| Literature DB >> 31176669 |
Amrit Singh1, Mary He2, Virginia Chen3, Zsuzsanna Hollander3, Scott J Tebbutt4, Raymond T Ng3, Bruce M McManus1, Don D Sin4, Felix Ratjen5, Bradley S Quon6.
Abstract
In CF, pulmonary exacerbations (PEx) can lead to permanent loss in lung function and thus should be prevented. Previously, we identified a blood protein biosignature consisting of 6 proteins capable of predicting short-term PEx events in CF adults. In this study, we utilized blood samples from the placebo arm of a randomized controlled trial to assess whether this candidate protein biosignature was also capable of predicting short-term PEx events in CF children and adolescents. This pilot study provides preliminary evidence that blood inflammation can be monitored to predict short-term PEx risk in CF children and adolescents.Entities:
Keywords: Biomarkers; Proteomics; Pulmonary exacerbations
Mesh:
Substances:
Year: 2019 PMID: 31176669 DOI: 10.1016/j.jcf.2019.05.020
Source DB: PubMed Journal: J Cyst Fibros ISSN: 1569-1993 Impact factor: 5.482